Founded in 2009 by leading experts in microbial research and drug discovery, Second Genome is developing a proprietary, first-in-class microbiome drug discovery platform to develop novel therapeutics in a range of diseases.

By bringing microbiome science to the discovery and development of therapeutic products, Second Genome has established a pipeline of therapeutic candidates for inflammatory bowel and metabolic diseases. Our development pipeline is fueled by novel technologies for identifying, screening, and scientifically validating product candidates through a comprehensive understanding of host-microbe interaction and the resulting implications in driving disease.

Founded on groundbreaking science from Lawrence Berkeley National Laboratory with the support of veteran biotechnology entrepreneurs, our technologies have been validated through partnerships with leading pharmaceutical and nutrition companies, as well as academic and governmental research institutions. The company is backed by investors with a track record of value creation, including Advanced Technology Ventures and Morgenthaler Ventures.